The PRIMA II is an investigator-initiated , multicenter , randomized , controlled , prospective @-arm trial that investigates the impact of inhospital guidance for ADHF treatment by a predefined NT-proBNP target ( > @ % reduction during admission ) on the reduction of readmission and mortality rates within @ days .